Friday, August 8, 2025

Invetech & AiCella Partner to Advance Cell Therapy Innovation

Related stories

Synechron Enhances Cybersecurity with AI Accelerators

Synechron, a global digital transformation consulting firm, has expanded...

Google Announces Gemini CLI GitHub Actions in Public Beta

Google announced the launch of Gemini CLI GitHub Actions,...

BigID Unveils Shadow AI Tool to Find Rogue Models & Risks

BigID, the leading platform for data security, privacy, compliance,...
spot_imgspot_img

Invetech, a global leader in solving complex manufacturing and product development challenges in the advanced therapies and diagnostics markets, announced a strategic collaboration with AiCella, a company focused on harnessing the power of artificial intelligence (AI) to optimize the development of cell therapy production processes and maximize patient response to treatment.

This partnership brings together Invetech’s deep domain expertise in End-to-End custom automation with AiCella’s cutting-edge artificial intelligence platform to deliver smarter, faster, and more cost-effective solutions for the industry – accelerating innovation and improving outcomes across the cell therapy landscape.

Also Read: Causaly Launches AI Competitive Intelligence for Scientists

“This collaboration is about more than just combining technologies—it’s about solving some of the most persistent challenges in cell therapy production,” said Andreas Knaack, President of Invetech. “By integrating AiCella’s predictive AI models with our proven technology platforms, we aim to help therapy developers identify critical process parameters earlier, reduce manufacturing variability, and ultimately accelerate the path to scalable, patient-ready therapies.”

“Our goal at AiCella is to uncover the hidden relationships between process inputs and patient outcomes—insights that traditional methods often miss,” said Geoffrey Stephens, PhD, CEO and Founder of AiCella. “Through this collaboration with Invetech, we’re embedding our AI models directly into the development and manufacturing lifecycle. This allows us to not only optimize process performance but also to generate data-driven hypotheses about which parameters most influence therapeutic efficacy—bringing us closer to truly personalized, responsive cell therapies.”

Source: PRNewswire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img